浙江昂利康制药股份有限公司 关于回购公司股份的进展公告 证券代码：002940 证券简称：昂利康 公告编号：2025-068 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"）于 2024 年 11 月 4 日召 开第四届董事会第六次会议，审议通过了《关于回购公司股份方案的议案》，同 意公司使用自有资金及股票回购专项贷款以集中竞价的方式回购公司部分已发 行的社会公众股份，回购的股份将用于后续员工持股计划或者股权激励。本次回 购股份的资金总额不低于人民币5,000万元（含）且不超过人民币7,000万元（含）， 回购价格不超过人民币 21.07 元/股（含）。具体回购股份的数量以公司实际回购 的股份数量为准。本次回购股份的实施期限为自董事会审议通过本次回购股份方 案之日起不超过 12 个月。具体内容详见公司于 2024 年 11 月 5 日、2024 年 11 月 8 日在指定信息披露媒体《证券时报》及巨潮资讯网（www.cninfo.com.cn）上 刊载的《关于回购公司股份方案暨收到<贷款承诺书>的公告》（公告编号： ...

Market Overview - The Shanghai Composite Index closed at 3875.53 points, with a change of 0.46% [1] - The total trading volume of A-shares reached 27,776.47 billion yuan [1] Technical Analysis - A total of 63 A-shares experienced a "death cross" where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Haitai Biological: 5-day MA at 50.56 yuan, 10-day MA at 51.97 yuan, a difference of -2.72% [1] - Titan Technology: 5-day MA at 27.25 yuan, 10-day MA at 27.85 yuan, a difference of -2.16% [1] - Anglikang: 5-day MA at 50.17 yuan, 10-day MA at 51.27 yuan, a difference of -2.15% [1] Individual Stock Performance - Haitai Biological: Today's change of -2.67%, with a turnover rate of 8.82% [1] - Titan Technology: Today's change of -2.29%, with a turnover rate of 4.22% [1] - Anglikang: Today's change of -0.85%, with a turnover rate of 6.98% [1] - Other stocks with notable performance include: - Rainbow Group: Today's change of -0.13%, with a turnover rate of 3.47% [1] - Wanli Stone: Today's change of -0.51%, with a turnover rate of 2.18% [1] Additional Observations - The market shows a trend of declining stock prices for several companies, indicating potential bearish sentiment [1][2] - The analysis of moving averages suggests a cautious approach for investors focusing on these stocks [1][2]

Market Overview - The Shanghai Composite Index is at 3864.71 points with a change of 0.18% [1] - The total trading volume of A-shares is 138.21 billion yuan [1] Technical Analysis - 62 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Haitai Biological: 5-day MA is -2.28% below the 10-day MA [1] - Titan Technology: 5-day MA is -2.07% below the 10-day MA [1] - Anglikang: 5-day MA is -1.88% below the 10-day MA [1] Individual Stock Performance - Haitai Biological (300683): Today's change is +1.95%, with a 5-day MA of 51.01 yuan and a 10-day MA of 52.20 yuan [1] - Titan Technology (688133): Today's change is -1.41%, with a 5-day MA of 27.30 yuan and a 10-day MA of 27.88 yuan [1] - Anglikang (002940): Today's change is +1.84%, with a 5-day MA of 50.44 yuan and a 10-day MA of 51.40 yuan [1] - Other stocks with notable performance include: - Rainbow Group (300314): +0.04% change, 5-day MA of 23.44 yuan [1] - Wanli Stone (002785): -0.89% change, 5-day MA of 29.62 yuan [1] Summary of Stocks with Death Cross - A list of stocks experiencing a death cross includes: - Haitai Biological, Titan Technology, Anglikang, and others with varying degrees of percentage differences between their moving averages [1][2]

Company Overview - Angli康 is a pharmaceutical company based in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company specializes in the research, production, and sales of chemical raw materials and formulations [1]. - The main business revenue composition includes formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1]. Stock Performance - As of September 1, Angli康's stock price increased by 2.00% to 50.41 CNY per share, with a trading volume of 215 million CNY and a turnover rate of 2.34%, resulting in a total market capitalization of 10.169 billion CNY [1]. - Year-to-date, Angli康's stock price has risen by 286.05%, but it has seen a decline of 9.37% over the last five trading days and 22.09% over the last 20 days. In the last 60 days, the stock price increased by 134.92% [1]. Financial Performance - For the first half of 2025, Angli康 reported a revenue of 724 million CNY, a year-on-year decrease of 14.52%, and a net profit attributable to shareholders of 65.925 million CNY, down 3.19% year-on-year [2]. - Since its A-share listing, Angli康 has distributed a total of 341 million CNY in dividends, with 108 million CNY distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, Angli康 had 18,500 shareholders, an increase of 50.49% from the previous period. The average number of circulating shares per person decreased by 33.55% to 10,037 shares [2]. - Notable new institutional shareholders include China Europe Medical Health Mixed A, holding 6.4373 million shares, and Guangfa Technology Innovation Mixed A, holding 6.1606 million shares [3].

Investment Rating - The report provides a positive outlook on the MASH non-invasive diagnosis technology, suggesting it could accelerate new drug development in the pharmaceutical and biotechnology sector [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.65% from August 25 to August 29, underperforming compared to the Wind All A index (1.9%) and the CSI 300 index (2.71%). Only the medical research outsourcing (4.9%) and other biological products (0.14%) sectors saw gains, while in vitro diagnostics (-4.12%), raw materials (-3.34%), and vaccines (-0.59%) faced significant declines [2][7]. - The FDA has accepted the proposal for using VCTE-LSM as a reasonable alternative endpoint for clinical trials in adults with MASH and moderate to advanced fibrosis. This non-invasive method is expected to enhance patient compliance and could lead to a surge in drug development in the MASH area within the next two to three years [2][13]. - The report emphasizes the potential for domestic companies in China to leverage their cost advantages and forward-looking strategies in the field of non-invasive companion diagnostics, particularly in the MASH drug development competition [2]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance was notably weaker than the broader market indices, with specific sub-sectors like medical research outsourcing and other biological products showing resilience [7][8]. - Individual stocks such as Tianchen Medical (30.1%), Ailis (25.6%), and Maiwei Biotech-U (22.4%) performed well, while stocks like Lifang Pharmaceutical (-13.9%), Yuekang Pharmaceutical (-11.9%), and Kanghua Biotech (-11.1%) faced significant losses [10][12]. Industry News and Key Company Announcements - On August 28, Kangfang Biotech announced that its drug AK112 received approval for treating advanced non-squamous non-small cell lung cancer, with promising clinical trial results expected to be presented at an international conference [12]. - The report highlights various companies' financial performances, with notable revenue changes and profit margins, indicating a mixed outlook across the sector [16][17].

Group 1: Company Insights - Kangliang Pharmaceutical's first innovative drug ALK-N001/QHL-1618 is expected to receive clinical approval in April 2025, currently in Phase I trials with two dose escalations completed [1] - Mindray Medical has launched the world's first clinically implemented critical care large model, named Qiyuan, and has established a subsidiary for animal healthcare [2] - Transsion Holdings is focusing on user value with its Practical I strategy, enhancing AI features in mid-range products, and has achieved a market share of nearly 40% in the Philippines [3] Group 2: Financial Performance and Strategy - Kangliang Pharmaceutical's R&D budget is capped at approximately 300 million yuan, with a significant reduction in generic drug investment starting in 2026 [1] - Mindray Medical's imaging solution "Ruiying·AI+" was developed in collaboration with DeepSeek, indicating a strategic push into AI-driven medical imaging [2] - Transsion Holdings reported a 1.49 percentage point increase in gross margin to 20.76% in Q2 2025, with R&D expenses primarily directed towards AI technology and mid-to-high-end imaging [3] Group 3: Market Position and Future Outlook - Huate Gas has entered the supply chain of major domestic GaN and SiC manufacturers, indicating strong positioning in the semiconductor market [3] - Jialian Technology is ramping up production capacity in Thailand, with plans to enhance efficiency through automation and has established partnerships in the 3D printing sector [3]

Summary of Key Points Overall Viewpoint - The report highlights that overseas attention is focused on industry tariffs, economic performance, interest rate guidance, and liquidity impacts, with U.S. stock funds preemptively defensive and rotating into interest rate-sensitive sectors such as finance, healthcare, and real estate, as well as U.S. Treasuries and gold benefiting from potential interest rate cuts [3][11][12] - Domestic economic marginal slowdown is noted, but key industries continue to expand, with supply-demand conflicts gradually easing and price indices recovering, making a halt in PPI decline expected [3][11] - The A-share market is anticipated to experience a volatile upward trend supported by three major rebalancing factors, with a focus on technology rotation, interest rate-sensitive trades, and industries benefiting from PPI recovery [3][11][18] Industry and Stock Logic - **Electronics: Lens Technology (300433.SZ)**: The company is expected to achieve total revenue of 69.9 billion yuan in 2024, a year-on-year increase of 28.27%, and a net profit of 3.62 billion yuan, up 19.94%, driven by vertical integration strategies and growth in assembly business [19][22] - **Networking: Shengke Communication-U (688702.SH)**: The company reported a revenue of 508 million yuan in the first half of 2025, a decrease of 4.56%, but a net profit of -24 million yuan, showing a significant year-on-year increase of 58.36% [23][24] - **Electronics: Shengyi Technology (688183.SH)**: The company achieved a revenue of 4.687 billion yuan in 2024, a year-on-year increase of 43.19%, and a net profit of 332 million yuan, turning profitable [28][29] - **Small Cap: Siquan New Materials (301489.SZ)**: The company reported a revenue of 656 million yuan in 2024, a year-on-year increase of 51.1%, with a net profit of 52.45 million yuan, a slight decrease of 3.88% due to increased expenses from new subsidiaries [36][37] - **Automotive: Moulded Technology (000700.SZ)**: The company is expected to generate total sales of 2.04 billion yuan from a luxury car manufacturer and a North American client, with production starting in 2026 [39][40] Key Stock Picks - The report lists ten key stocks, including Lens Technology, Shengke Communication-U, Shengyi Technology, Siquan New Materials, and Moulded Technology, among others, with no specific ranking [4][10]

Core Viewpoint - The company, Anglikang, reported a revenue of 724 million yuan in the first half of 2025, with significant contributions from its formulation, API, and specialty intermediates businesses, indicating a positive growth trajectory despite market fluctuations [1][2]. Financial Performance - In H1 2025, the company achieved revenues of 315 million yuan from formulations, 288 million yuan from APIs, and 90.12 million yuan from specialty intermediates, with gross margins of 46.67%, 21.94%, and 70.20% respectively [1]. - The company's R&D investment reached 85.6 million yuan, accounting for 11.82% of its revenue, highlighting its commitment to innovation [1][4]. Business Structure and Market Strategy - The company maintains a diversified business structure, with domestic sales accounting for 75.85% and international sales for 24.15%, focusing on large pharmaceutical and feed enterprises [2]. - Through a combination of direct sales and deep distribution, the company has established a stable market foundation in the chemical API and formulation sectors [2]. R&D and Innovation - The company is advancing its innovation strategy, with multiple new drug projects entering clinical stages, including ALK-M001/BM2216 and ALK-N001/QHL-1618 [1][4]. - In H1 2025, the company secured four invention patents and five utility model patents, reflecting its strong focus on R&D [4]. Strategic Collaborations - The company signed a licensing agreement with Yafei Biopharmaceutical and Qinhuli Biopharmaceutical to develop the innovative drug ALK-N002/IMD-1005, which targets CD47 for cancer treatment [5][6]. - This collaboration aims to enhance the company's product portfolio in the oncology sector, leveraging unique drug design for improved therapeutic outcomes [6][7]. Market Expansion in Emerging Sectors - The company is actively expanding into the pet medicine and nutrition market, which is projected to grow significantly, with the pet medicine market expected to increase from 9.39 billion yuan in 2020 to 20.95 billion yuan by 2024, reflecting a compound annual growth rate of 22.2% [8]. - The company has made progress in its pet medicine R&D projects, completing several product registrations and enhancing market recognition through initiatives like the "Angmai Cup" veterinary anesthesia case competition [8]. Future Outlook - Anglikang aims to continue its growth trajectory by integrating resources to optimize product layout and transitioning from a focus on generic drugs to a model that includes specialty generics, modified new drugs, and innovative drugs [9]. - The company is committed to sustainable development and enhancing its brand recognition in the modern pharmaceutical industry [9].

证券日报网讯昂利康8月29日发布公告，在公司回答调研者提问时表示，从公司整体战略来看，未来改 良型新药和创新药将成为公司研发的重点，鉴于创新药研发费用投入较大，预计未来几年其投入占比将 逐步超过改良型新药。短期内，公司创新药管线主要包括两个项目：ALK-N001/QHL-1618针对化疗， ALK-N002/IMD-1005则聚焦于免疫治疗。除肿瘤治疗方向之外，公司也在评估其他治疗领域和方向的 创新药布局机会，以不断完善产品管线结构。截至目前，改良型新药ALKA016-1已完成申报注册； NHKC-1、BM2216缓释片目前正处于临床阶段。在改良型新药的选择上，未来主要依托公司现有的复 方、缓控释、透皮、复杂注射剂等技术平台，探索新的管线产品。 （文章来源：证券日报） ...

Core Viewpoint - The company announced that its innovative drug products are currently in the early clinical stages, with a focus on building clinical and medical teams [2] Group 1 - The company is prioritizing the establishment of clinical and medical teams at this stage [2] - Future commercialization plans for related products will depend on the progress of clinical research [2] - The company aims to leverage clinical research outcomes to plan and advance its product commercialization at the appropriate time [2]